Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia.
Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia.
复制标题
以发病机制为导向的治疗皮质类固醇耐药或复发性原发性免疫性血小板减少症的方法
DOI：
10.1515/med-2016-0019
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Hou M
中科院分区：
文献类型：
--
作者：
Liu XG;Hou M
原发性免疫性血小板减少症（ITP）是一种复杂的自身免疫性疾病，其中患者的免疫系统与血小板自身抗原反应，导致免疫介导的血小板破坏和/或血小板产生抑制。皮质类固醇可诱导50%至75%的活动性ITP患者的持续缓解率。对于这些对糖皮质激素无反应或在初始反应后复发的患者，可以选择多种二线治疗方式。然而，如何为特定患者制定最佳治疗策略仍然是一个重大挑战。随着ITP发病机制的异质性日益被发现，以发病机制为导向的方法可能会提供一个机会，以改善皮质类固醇耐药或复发性ITP的结果。
Primary immune thrombocytopenia (ITP) is a complex autoimmune disorder in which the patient’s immune system reacts with platelet autoantigens resulting in immune-mediated platelet destruction and/or suppression of platelet production. Corticosteroids can induce sustained remission rates in 50% to 75% of patients with active ITP. For these patients who are unresponsive to glucocorticoids, or relapsed after an initial response, multiple second-line treatment modalities can be chosen. However, how to make an optimal therapeutic strategy for a specific patient still remains a major challenge. As the pathogenetic heterogeneity of the ITP is increasingly identified, pathogenesis-oriented approach might offer an opportunity to improve the outcome of corticosteroid-resistant or relapsed ITP.